Paediatrics

Gene therapy
#Clinical trial #Gene therapy #Genetics / genomics #Hearing Loss #Paediatrics #Regeneron Pharmaceuticals

Gene therapy restores hearing in both ears

Five children who were born with congenital hearing loss can hear in both ears after taking part in a gene therapy trial at Fudan University in Shanghai, China. Within weeks of receiving the therapy, the children could locate the sources of sounds, and recognised speech in… Read More

#News

Herpes virus cells
#Brain cancer #CureSearch #Herpes virus #LifeArc #MD Anderson Cancer Center #Oncology #Paediatrics

Could a modified cold sore virus cure brain cancer?

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The three-year survival rate for children with high-grade gliomas, without further complications, is only… Read More

#Cancer Research #Editor's Choice #News

Child having a hearing test
#Gene mutation #Gene therapy #Genetic diseases #Hearing Loss #Paediatrics #Rare disease

Gene therapy cures profound genetic deafness within 24 weeks

The investigational gene therapy DB-OTO improved hearing to normal levels in a child (dosed at 11 months of age) within 24 weeks, according to trial data presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference. Initial hearing improvements have also been observed… Read More

#News #Trending News

CAR-T therapy
#Blood cancer #Leukaemia #National Institute for Health and Care Excellence (NICE) #Oncology #Paediatrics

UK’s NICE supports CAR-T for young people with leukaemia

The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Kymriah (tisagenlecleucel) for treating paediatric and young adults up to the age of 25 with B-cell acute lymphoblastic leukaemia (ALL). It is approved in cancers that are refractory, in relapse post-transplant or in second or later relapse. The… Read More

#News #Regulatory

#Cystic fibrosis #Ireland #Paediatrics #Respiratory #Vertex

Landmark study supports use of cystic fibrosis drug in newborns

A cystic fibrosis drug targeting the basic defect that causes the condition has been shown to be safe and effective in newborns aged four weeks and above, new research has found. The study, involving RCSI University of Medicine and Health Sciences and Children’s Health Ireland, included… Read More

#News

Cell and gene therapy
#FDA #Gene editing #Gene therapy #iECURE #In vivo #Paediatrics

FDA approves first in vivo gene insertion programme in infants

iECURE has been given the go-ahead to begin US trials of its investigational gene editing-based therapy in newborn males with neonatal onset Ornithine Transcarbamylase (OTC) deficiency. The Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for ECUR-506 makes it the first in vivo gene… Read More

#Editor's Choice #News

Gene therapy
#Cell and gene therapy #FDA #Gene therapy #Orchard Therapeutics #Paediatrics #Rare disease

First gene therapy for children with rare disease gets US sign-off

Lenmeldy (atidarsagene autotemcel) has become the first Food and Drug Administration (FDA)-approved gene therapy for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD). Metachromatic leukodystrophy is a debilitating, rare genetic disease affecting the brain and nervous system. It is… Read More

#News #Regulatory #Trending News

FDA
#Astellas Pharma #FDA #Orphan drugs #Paediatrics

FDA grants orphan and paediatric exclusivities for Cresemba

The US Food and Drug Administration (FDA) has granted orphan drug and paediatric exclusivity to Cresemba (isavuconazonium sulfate) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in paediatric patients. In December 2023, Cresemba for injection was approved for paediatric patients one year of age and older and… Read More

#News #Regulatory

Checking a baby's glucose levels
#Breast cancer #Drug repurposing #Endocrinology #Paediatrics #Sidra Medicine

Breast cancer drug repurposed for congenital hyperinsulinism

In a world first, Sidra Medicine, a member of Qatar Foundation, has pioneered a new treatment protocol for a young infant with congenital hyperinsulinism. The findings were published in the New England Journal of Medicine. As the patient wasn’t responding to conventional medical therapies, the Sidra… Read More

#News

Handshake jigsaw puzzle
#Cancer #Clinical trials #Drug development #Paediatrics

Advancing paediatric cancer research through partnerships 

Paediatric oncologist Gauri Sunkersett shares her unique background and research approach at AbbVie to help find answers for the youngest blood cancer patients.   When I was a second-year resident training as a paediatric oncologist at Nicklaus Children’s Hospital, I met a teenage boy diagnosed with Hodgkin’s Lymphoma. He was admitted… Read More

#Exclusive Content

Cancer research
#Clinical trials #Paediatrics #Pharming #Phase III trial #Rare disease

Trials investigate targeted APDS treatment in a paediatric setting

The first patient has been dosed in a Phase III study evaluating a paediatric granulated formulation of leniolisib in children with activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming’s investigational drug leniolisib is an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. At sites in the… Read More

#News

Mother helps child to use a nebuliser
#Cystic fibrosis #European Commission #Gene mutation #Genetics / genomics #Paediatrics #Vertex

EU extends paediatric use of combination in cystic fibrosis

A label expansion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) has been approved in the European Union (EU). The European Commission has extended use of the therapy to include children with CF aged two through five years old who have at… Read More

#News #Regulatory

Hematopoietic cells
#Cancer research #Clinical trial #Gene therapy #MHRA #Paediatrics #Phase I trial #Stem cells #UK

First gene therapy trial for Hunter syndrome opens in Manchester, UK

UK regulatory authorities have approved the first trial of a gene therapy for young children with Hunter syndrome. The UK Medicines and Healthcare Products Regulatory Agency (MHRA), Research Ethics Committee (REC), and Health Research Authority (HRA) have all approved the clinical trial application that was submitted by The University of… Read More

#Editor's Choice #News #Regulatory

Saline intravenous (iv) drip in a child's hand
#Charles River #Human disease models #Oncology #Paediatrics #Preclinical investigations

Paediatric models for preclinical testing of oncology drugs

The US Food and Drug Administration’s (FDA) Research to Accelerate Cures and Equity (RACE) for Children Act now requires all oncology drugs to be tested for paediatric indications ahead of approval. The EU regulation of the European Medicines Agency (EMA) is also being adapted to mirror… Read More

#Cancer Research #News

Doctor points at child's brain scan
#Francis Crick Institute #Gene therapy #Great Ormond Street Hospital #Paediatrics #Rare disease

Researchers design genetic therapy to prevent brain deterioration

A research team at the Francis Crick Institute and Great Ormond Street Hospital (GOSH)/UCL Great Ormond Street Institute of Child Health have identified potential treatments for children with rare genetic conditions. The researchers have shown that problems with calcium underlie these progressive diseases. Stabilising calcium levels… Read More

#Editor's Choice #News

European Commission
#Chemotherapy #European Commission #Jazz Pharmaceuticals #Leukaemia #Paediatrics

EC approves Erwinia-derived asparaginase for leukaemia

The European Commission (EC) has granted marketing authorisation for Jazz Pharmaceuticals’ Enrylaze as part of a multi-agent regimen for acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). The treatment is approved in adult and paediatric patients who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. Enrylaze, approved as Rylaze… Read More

#News #Regulatory